Falls are common in persons with Multiple Sclerosis (pwMS) and lead to destructive results, specifically with increasing disability. However, there is only scarce data investigating prevalence and determinants of falls in pwMS without a clinical disability. Therefore, this study aimed to investigate proportion of fallers and related factors in pwMS without a clinical disability. One hundred and four pwMS with no clinical disability (EDSS≤1.5) were recruited in this cross-sectional study. The outcome measures comprised of the Timed 25-Foot Walk (T25FW), Six Minute Walk Test (6MWT), Timed Up and Go Test (TUG), Multiple Sclerosis Walking Scale (MSWS-12), Single Leg Stance Test (SLS), Activities-Specific Balance Confidence Scale (ABC), Symbol Digit Modalities Test (SDMT), Modified Fatigue Impact Scale (MFIS), and Beck Depression Inventory-II (BDI-II). The number of falls during the last three months was recorded. Twenty-five percent of the pwMS reported at least one fall in the last three months. The TUG anpredict potential fallers of the pwMS without a clinical disability. Self-reported outcomes are important for epidemiological research but are vulnerable to bias. In this study, we evaluated 1) the consistency and validity of self-reported year of diagnosis among people living with MS, 2) factors associated with participant inconsistency, and 3) the impact of observed inconsistency on the calculation of the Multiple Sclerosis Severity Score (MSSS). Using data collected by the Australian MS Longitudinal Study, we evaluated the consistency of self-reported year of diagnosis using correlation, mean differences, and percentage agreement. We examined the impact of participant characteristics using Cragg hurdle models, and determined the effect of the observed inconsistency on MSSS using simulations compared with paired t-tests. Of the 2,445 participants, 80.3% were within 1 year of their baseline year of diagnosis in all subsequent responses (range of 2-10 responses). Participant inconsistency was positively associated with age at first response and the number of years elapsed between the first and final response. However, the effect sizes of these associations were small. Finally, the observed inconsistency did not affect the calculation of MSSS (mean difference smaller than 0.01; p>0.90 for all comparisons). This data provides support for the use of patient-reported year of diagnosis, as people with MS were consistent in reporting their year of diagnosis and the impact of any inconsistency on clinical outcomes, such as the MSSS, was negligible.This data provides support for the use of patient-reported year of diagnosis, as people with MS were consistent in reporting their year of diagnosis and the impact of any inconsistency on clinical outcomes, such as the MSSS, was negligible. The 2,2-dihydroxymethyl-1-[ F]fluoropropane group, also called F-labelled neopentyl glycol side-chain, is a novel F-labelling group for positron emission tomography (PET) imaging agents. The aim of using this group is to develop simple purification with solid-phase extraction without high-performance liquid chromatography. However, the effects of the neopentyl F-labelling group on the characteristics of brain imaging agents are unknown. Here, we added this side-chain to compounds with an aminostilbene structure to evaluate their effects on the biological properties of aminostilbene as an amyloid-β (Aβ) radioligand. Biodistributions of four novel F-labelled stilbene compounds with different lengths of polyethylene glycol (PEG) linkers, called [ F]Cpd-0, -1, -2, and -4, (PEG=0, 1, 2, and 4), and [ F]AV-1 in normal mice were evaluated. Metabolite analysis of [ F]Cpd-0 and -1 was performed with mouse plasma and brain. A competitive binding assay of [ F]AV-1 binding to Aβ fibrils was performed preferable pharmacokinetic properties as a brain imaging radioligand in normal mice. These side-chains can be used as an alternative labelling group for imaging agents targeting the brain.In chronic neurological conditions, wearable/portable devices have potential as innovative tools to detect subtle early disease manifestations and disease fluctuations for the purpose of clinical diagnosis, care and therapeutic development. Huntington's disease (HD) has a unique combination of motor and non-motor features which, combined with recent and anticipated therapeutic progress, gives great potential for such devices to prove useful. The present work aims to provide a comprehensive account of the use of wearable/portable devices in HD and of what they have contributed so far. We conducted a systematic review searching MEDLINE, Embase, and IEEE Xplore. Thirty references were identified. CID44216842 Our results revealed large variability in the types of sensors used, study design, and the measured outcomes. Digital technologies show considerable promise for therapeutic research and clinical management of HD. However, more studies with standardized devices and harmonized protocols are needed to optimize the potential applicability of wearable/portable devices in HD. Emerging evidence has suggested that cerebral small vessel disease (CSVD) may worsen motor function and cognition in Parkinson's disease (PD). However, the effect of CSVD on anxiety and depression in patients with PD remains unknown. This study explored the multi-dimensional effects of CSVD on PD outcomes (motor, cognition, and depression/anxiety). This cross-sectional study included 431 patients with PD from Beijing Tiantan Hospital from May 2016 to August 2019. CSVD imaging markers were assessed and the four-point CSVD burden score was calculated. Motor function (MDS-UPDRS III score and subscores), cognition (MMSE, MoCA), anxiety (HAMA), and depression (HAMD) were assessed in these patients. The associations of CSVD with these outcomes were analyzed using the Spearman's correlation and multivariable linear regression models. Motor dysfunction, cognitive impairment, depression, and anxiety were significantly worse in patients with severe CSVD than in those with mild CSVD. Multivariable linear regression showed that CSVD burden was significantly associated with motor dysfunction (MDS-UPDRS III score and rigidity and bradykinesia subscores), impaired cognition, and high levels of depression and anxiety.